Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's top 2 picks
Investing Experts
Exploring Promising Biotech Investments: Tarsus and SpringWorks
This chapter explores Tarsus Pharmaceuticals and SpringWorks Therapeutics, highlighting Tarsus's drug Xdemvi for demodex blepharitis and SpringWorks's Oxivio for desmoid tumors. The discussion emphasizes the strong market prospects and growth potential of both companies as attractive investment opportunities.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
